Srebf2 was significantly upregulated (p < 0.05) in breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), and lung squamous cell carcinoma (LUSC), while significantly downregulated (p < 0.05) in colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD) and pheochromocytoma and paraganglioma (PCPG) (Figure 8). This evidence concerns the gene SREBF2 and lung adenocarcinoma.